Improving the chances of successful research funding
The fact that symptoms of lung disease are so ubiquitous seems to imply to some that respiratory medicine is not a specialty field deserving dedicated support in its own right. Even today it is not uncommon to hear the view expressed that respiratory medicine ceased to have importance when that sometimes heroic infectious disease tuberculosis was conquered. When this stand is challenged, the further riposte is that only lung cancer and chronic bronchitis remain: it is maintained that both are intractable and of no public concern since they are the sole responsibility of the unheeding patient who persists in smoking cigarettes despite repeated health warnings from the Government (and the Royal College of Physicians).
This view, of course, expresses only an ignorance of the facts. Nevertheless, such a concept of respiratory medicine does not augur well either for those trying to raise money or for those who need to convince their peers in other specialties of the opportunities in and importance of research on lung disease.
Currently there appears to be a vicious circle, where lack of recognition of the importance of respiratory medicine to the community is leading to lack of research funding. This in turn reduces the number of individuals working in this area, which further reduces public awareness of the need. This downward spiral must be reversed.
THE BURDEN OF RESPIRATORY DISEASE IN RELATION TO FUNDING OF RESEARCH
If the burden of respiratory disease is to be reduced, much more research on pathogenesis, treatment, and prevention is needed. The fact is that much important lung disease is not related to smoking-asthma, cystic fibrosis, and cot deaths are just three examples. A very wide range of lung disease is found, affecting all ages and all classes. There are few people who do not known of some family member with chest disease. Inappropriate breathlessness, that distressing cardinal symptom of lung impairment, is experienced by almost everyone at some time during their lifespan.
Disease in almost every organ and system of the body may present with pulmonary manifestations and the lungs continue as the predominant site of disease in many patients. A wide range of industrial lung diseases is of increasing public concern. Respiratory disease covers a huge range, from the horrendously common to the fascinatingly rare.
The burden of deaths and disability from various diseases in relation to research support is shown in the figure and emphasises the scale of the problem in respiratory medicine within the United Kingdom. This disparity between burden of disease and resources for research is much less striking in other countries. Both North America and the continent of Europe have shown that the status of respiratory medicine can be far more impressive than is the case in the UK. The American Thoracic Society has some 8000 members and their investment of effort and money in pulmonary research is booming, because they have realised that so many basic scientific disciplines can now be applied to the study of diseased and healthy lungs and there is absolutely no shortage of exciting avenues for research.
NEW OPPORTUNITIES IN RESPIRATORY RESEARCH
New techniques are available to look at basic mechanisms of respiratory disease. Such techniques cover the disciplines of biochemistry, pharmacology, immunology, radiobiology, microbiology, cell biology, and experimental pathology. The lung is accessible not only through biopsies of various types, which are far more acceptable than previously, but also through the development of the techniques of lung lavage. A whole gamut of new technology can be applied to material obtained in these ways, especially the use of the new tools of cell and molecular biology. A few examples may be cited. Study of individual cell membrane receptors, the location of vasoactive peptides, and the identification of many specific humoral mediators have all proved fascinating. Electron probe analysis applied to individual cells of the lung enables the precise elements contained within them to be analysed. The biochemistry of the lung architecture as well as cell profiles and localisation of inflammation using monoclonal antibody techniques is giving new insight into mechanisms of lung damage and repair. The role of the lung as an organ of great immunological responsiveness both to external and to circulating agents provides a unique model for immunologists concerned with basic mechanisms of host 817 Firstly, let no one be able to criticise our case. Through better publicity we need to show that the subject is of great public concern and that there is an urgent need for important work to be done where the ideas and techniques are waiting for development. Those of us working in this area have to face the fact that more good applications to existing organisations should be submitted.
The first step in securing any research funds is to apply for them. This is not as obvious as it may seem. There are substantial disincentives to writing in detail an application that at best requires four or five drafts and takes several weeks to prepare. In many instances there is a lapse of as much as six to nine months before the outcome is known. In the meantime, and all too often, the worker whose salary is needed has taken other employment. Even when the application is successful, the limited resources of the grant giving bodies mean that the costs are often substantially slashed, so that the project becomes almost nonviable. As a carry over from more affluent days, many grant giving bodies do not believe that it is right to contribute to overheads, yet with university cuts such overheads cannot easily be covered from elsewhere. The current position with regard to funding from research councils, charities, and the pharmaceutical industry was reported by representatives from these bodies at a special symposium held during the British Thoracic Society winter meeting, 1985
